# Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension

> **NCT02220634** · NA · TERMINATED · sponsor: **National Jewish Health** · enrollment: 10 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Regadenoson

## Key facts

- **NCT ID:** NCT02220634
- **Lead sponsor:** National Jewish Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08
- **Primary completion:** 2017-05-25
- **Final completion:** 2017-05-25
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** PI left National Jewish Health
- **Last updated:** 2021-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02220634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02220634, "Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02220634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*